Blood thickening, or hypercoagulability, occurs when excess cells or clotting proteins make blood more viscous, increasing ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

My son has been diagnosed with a cerebrospinal fluid (CSF) leak. I had never heard of this. He has been told that his brain ...

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity ...

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to ...

The essential thrombocythemia market is expected to grow steadily due to increasing disease prevalence, advancements in targeted therapies, and risin ...

Rusfertide could become a blockbuster therapy for polycythemia vera, H.C. Wainwright analyst Douglas Tsao wrote March 4 after the injectable hepcidin mimetic peptide hit its primary endpoint and all ...

US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the ...

JPMorgan raised the firm’s price target on Protagonist Therapeutics (PTGX) to $57 from $53 and keeps an Overweight rating on the shares. The ...

DelveInsight's In Situ Hybridization Market Insights report provides the current and forecast market analysis, individual ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...